Cargando…

Prevalence of neurocognitive disorder in Huntington’s disease using the Enroll-HD dataset

BACKGROUND: Cognitive decline in Huntington’s disease (HD) begins early in the disease course, however the reported prevalence and severity of cognitive impairment varies based on diagnostic approach. A Movement Disorders Society Task Force recently endorsed the use of standardized DSM-5-based crite...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sierra, Luis A., Ullman, Clementina J., Baselga-Garriga, Clara, Pandeya, Sarbesh R., Frank, Samuel A., Laganiere, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375015/ https://www.ncbi.nlm.nih.gov/pubmed/37521291 http://dx.doi.org/10.3389/fneur.2023.1198145

Ejemplares similares

LASSI-L detects early cognitive changes in pre-motor manifest Huntington’s disease: a replication and validation study
por: Sierra, Luis A., et al.
Publicado: (2023)

Enroll-HD: An Integrated Clinical Research Platform and Worldwide Observational Study for Huntington's Disease
por: Sathe, Swati, et al.
Publicado: (2021)

The Clinical Picture of Psychosis in Manifest Huntington's Disease: A Comprehensive Analysis of the Enroll-HD Database
por: Rocha, Natalia P., et al.
Publicado: (2018)

Exploring the predictors of financial impairment in Huntington’s disease using the Enroll-HD dataset
por: Harris, Kate L., et al.
Publicado: (2022)

Clustering and prediction of disease progression trajectories in Huntington's disease: An analysis of Enroll-HD data using a machine learning approach
por: Ko, Jinnie, et al.
Publicado: (2023)

Machine learning in Huntington’s disease: exploring the Enroll-HD dataset for prognosis and driving capability prediction
por: Ouwerkerk, Jasper, et al.
Publicado: (2023)

Memantine Use and Cognitive Decline in Huntington's Disease: An Enroll‐HD Study
por: Ogilvie, Amy C., et al.
Publicado: (2023)

Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington’s disease (Enroll-HD)
por: Harris, Kate L, et al.
Publicado: (2020)

A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study
por: Langbehn, Douglas R., et al.
Publicado: (2023)

Understanding HD Psychosis: An Analysis from the ENROLL-HD Database
por: Jaini, Ashwin, et al.
Publicado: (2020)

Another Perspective on Huntington’s Disease: Disease Burden in Family Members and Pre-Manifest HD When Compared to Genotype-Negative Participants from ENROLL-HD
por: Achenbach, Jannis, et al.
Publicado: (2021)

HD_BPMDS: a curated binary pattern multitarget dataset of Huntington’s disease–targeting agents
por: Stefan, Sven Marcel, et al.
Publicado: (2023)

Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators
por: Frank, Samuel
Publicado: (2009)

Study Protocol for the Development of a European eHealth Platform to Improve Quality of Life in Individuals With Huntington's Disease and Their Partners (HD-eHelp Study): A User-Centered Design Approach
por: van Lonkhuizen, Pearl J. C., et al.
Publicado: (2021)

Genetic and Environmental Contributors to Neurodegeneration: An Exploration of the Effects of Alcohol on Clinical Features of Huntington’s Disease Using the Enroll-HD Global Platform
por: Symonds, Alexander L., et al.
Publicado: (2021)

Protocol for REducing Anti-Psychotic use in residential care-Huntington Disease (REAP-HD): a pilot cluster randomised controlled trial of a multifaceted intervention for health professionals
por: Loy, Clement T, et al.
Publicado: (2014)

Disease Burden of Huntington’s Disease (HD) on People Living with HD and Care Partners in Canada
por: Shaw, Eileen, et al.
Publicado: (2022)

Refining the diagnosis of Huntington disease: the PREDICT-HD study
por: Biglan, Kevin M., et al.
Publicado: (2013)

Molecule of the month: miRNA and Huntington's disease (HD)
por: Shapshak, Paul
Publicado: (2013)

Is Ataxia an Underestimated Symptom of Huntington's Disease?
por: Franklin, Gustavo L., et al.
Publicado: (2020)

Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study
por: Klöppel, Stefan, et al.
Publicado: (2015)

International Guidelines for the Treatment of Huntington's Disease
por: Bachoud-Lévi, Anne-Catherine, et al.
Publicado: (2019)

Detection of Huntington’s disease decades before diagnosis: the Predict-HD study
por: Paulsen, J S, et al.
Publicado: (2008)

Mild Cognitive Impairment as an Early Landmark in Huntington's Disease
por: Zhang, Ying, et al.
Publicado: (2021)

HD-PRO-TRIAD™ Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease
por: Carlozzi, Noelle E., et al.
Publicado: (2014)

Nrf2 Pathway in Huntington’s Disease (HD): What Is Its Role?
por: Tucci, Paolo, et al.
Publicado: (2022)

Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study
por: Dorsey, Ray, et al.
Publicado: (2011)

Memantine for the Treatment of Behavioral Disturbance in Unspecified Major Neurocognitive Disorder
por: Terry, Peyton H, et al.
Publicado: (2021)

HD-EEG Based Classification of Motor-Imagery Related Activity in Patients With Spinal Cord Injury
por: Höller, Yvonne, et al.
Publicado: (2018)

Targeting Tau to Treat Clinical Features of Huntington's Disease
por: Masnata, Maria, et al.
Publicado: (2020)

Case report: Cerebellar sparing in juvenile Huntington's disease
por: Santos-Lobato, Bruno Lopes, et al.
Publicado: (2023)

Release of Soluble Insulin Receptor From Neurons by Cerebrospinal Fluid From Patients With Neurocognitive Dysfunction and HIV Infection
por: Gerena, Yamil, et al.
Publicado: (2019)

Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntington’s Disease
por: Mansoor, Nina M., et al.
Publicado: (2021)

APOEε4 Genotype Is Related to Brain Amyloid Among Mexican Americans in the HABS-HD Study
por: O'Bryant, Sid E., et al.
Publicado: (2022)

The Prevalence of Frascati-Criteria-Based HIV-Associated Neurocognitive Disorder (HAND) in HIV-Infected Adults: A Systematic Review and Meta-Analysis
por: Wei, Jiaqi, et al.
Publicado: (2020)

Multivariate prediction of motor diagnosis in Huntington's disease: 12 years of PREDICT‐HD
por: Long, Jeffrey D., et al.
Publicado: (2015)

MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study
por: Reed, Eric R., et al.
Publicado: (2018)

DNA Methylation Profiles in Whole Blood of Huntington's Disease Patients
por: Zadel, Maja, et al.
Publicado: (2018)

Genetic Counseling in Huntington's Disease: Potential New Challenges on Horizon?
por: Migliore, Simone, et al.
Publicado: (2019)

Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review
por: Kinnunen, Kirsi M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_496ri852g4ou6o5ar3v714sn9g